Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains

Gene Therapy

Volumn 12, Issue 3, 2005, Pages 211-224

  Henning, P ^a,b   Andersson, K M E ^a   Frykholm, K ^a   Ali, A ^a   Magnusson, M K ^a   Nygren, P A ^c   Granio, O ^d   Hong, S S ^d   Boulanger, P ^d   Lindholm, L ^a,b  

^a Got A Gene AB   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Adenovirus; Cancer therapy; Fiber; Ig binding domain; Retargeting

Indexed keywords

ADENOVIRUS VECTOR; CA242 ANTIGEN; CELL RECEPTOR; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; STAPHYLOCOCCUS PROTEIN A; STREPTOCOCCUS PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RECEPTOR;

ADENOVIRUS 5; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BREAST CELL; CARCINOMA CELL; CELL STRAIN HEK293; CELL STRAIN HT29; COXSACKIE VIRUS B3; ENDOCYTOSIS; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; INTESTINE CELL; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; OVARY CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR AFFINITY; SEROTYPE; TARGET CELL; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; VIRUS FIBER;

ADENOVIRUSES, HUMAN; ANTIBODIES; BLOTTING, WESTERN; CAPSID PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MICROSCOPY, ELECTRON; NEOPLASMS; PROTEIN BINDING; TRANSDUCTION, GENETIC; VIRION; VIRUS INTEGRATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 13544257458     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302408     Document Type: Article

References (52)

1. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-2604.
2. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1: 391-405.
3. Bergelson JM et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275 1320-1323.
4. Hong SS et al. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997; 16: 2294-2306.
5. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
6. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-390.
7. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
8. Hong SS et al. Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity. Hum Gene Ther 1999; 10: 2577-2586.
9. Wickham TJ et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997; 71: 7663-7669.
10. van Beusechem VW et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 2002; 76: 2753-2762.
11. Soudais C et al. Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 2000; 74: 10639-10649.
12. Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing 'deknobbing' of the fiber. J Virol 2001; 75: 7280-7289.
13. Henning P et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 2002; 13: 1427-1439.
14. Magnusson MK et al. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002; 4: 356-370.
15. Nilsson B et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1987; 1: 107-113.
16. Nord K et al. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 1995; 8: 601-608.
17. Eliasson M et al. Differential IgG-binding characteristics of staphylococcal protein A, streptococcal protein G, and a chimeric protein AG. J Immunol 1989; 142: 575-581.
18. Harlow E, Lane D. Reagents. In: Harlow E, Lane D (ed). Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory: New York, 1988, pp 613-633.
19. Nagaoka M, Akaike T. Single amino acid substitution in the mouse IgG1 Fc region induces drastic enhancement of the affinity to protein A. Protein Eng 2003; 16: 243-245.
20. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
21. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397-406.
22. Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997; 45 210-215.
23. Volpers C et al. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin G-binding domain in the capsid. J Virol 2003; 77: 2093-2104.
24. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26: 51-59.
25. Baselga J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
26. Molina MA et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61 4744-4749.
27. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2002; 62: 609-616.
28. Baeckstrom D et al. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody. Cancer Res 1993; 53: 755-761.
29. Johansson C et al. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol 1991; 12: 159-170.
30. Debinski W, Pastan I. Recombinant F(ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Clin Cancer Res 1995; 1 1015-1022.
31. Calvete JA, Newell DR, Wright AF, Rose MS. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer. Cancer Res 1994; 54: 4684-4690.
32. Chang SS et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198.
33. Fracasso G et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002; 53: 9-23.
34. Smith-Jones PM et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44: 610-617.
35. Trainer DL et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988; 41: 287-296.
36. Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
37. Krasnykh V et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
38. van Beusechem VW et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy 2003; 10 1982-1991.
39. Jongmans W et al. Targeting of adenovirus to human renal cell carcinoma cells. Urology 2003; 62: 559-565.
40. Barker SD et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 2003; 10: 1198-1204.
41. Blackwell JL et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125: 856-863.
42. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2003; 5: 451-462.
43. Medina-Kauwe LK. Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev 2003; 55: 1485-1496.
44. Chroboczek J, Gout E, Favier AL, Galinier R. Novel partner proteins of adenovirus penton. Curr Top Microbiol Immunol 2003; 272: 37-55.
45. Miyazawa N, Crystal RG, Leopold PL. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol 2001; 75: 1387-1400.
46. Jendeberg L et al. Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. J Immunol Methods 1997; 201: 25-34.
47. Hong JS, Engler JA. The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal. Virology 1991; 185: 758-767.
48. Gülich S, Linhult M, Stahl S, Hober S. Engineering streptococcal protein G for increased alkaline stability. Protein Eng 2002; 15: 835-842.
49. Karayan L et al. Structural and functional determinants in adenovirus type 2 penton base recombinant protein. J Virol 1997; 71: 8678-8689.
50. Neumann R, Chroboczek J, Jacrot B. Determination of the nucleotide sequence for the penton-base gene of human adenovirus type 5. Gene 1988; 69: 153-157.
51. O'Reilly DR, Miller LK, Luckow VA. Virus Methods. In: Press OU (ed) Baculovirus Expression Vectors. A Laboratory Manual. Oxford, England, 1994, pp 124-138.
52. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.